

## RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

### **The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular Vesicles in Paroxysmal Nocturnal Hemoglobinuria Patients**

Wannez, Adeline; Devalet, Bérangère; Bouvy, Céline; Bihin, Benoît; Douxfils, Jonathan; Dogne, Jean-Michel; Mullier, François

*Published in:*  
Research and practice in thrombosis and haemostasis

*Publication date:*  
2017

*Document Version*  
Publisher's PDF, also known as Version of record

#### [Link to publication](#)

*Citation for published version (HARVARD):*  
Wannez, A, Devalet, B, Bouvy, C, Bihin, B, Douxfils, J, Dogne, J-M & Mullier, F 2017, The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular Vesicles in Paroxysmal Nocturnal Hemoglobinuria Patients. in *Research and practice in thrombosis and haemostasis: Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017*. vol. 1, pp. 1083, XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Germany, 8/07/17.

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**TABLE 1** Number of extracellular vesicles (EV), levels of D-dimer and CEA in venous blood of colorectal cancer patients before and during chemotherapy

	Before 1 <sup>st</sup> ChTx (baseline)	Before 2 <sup>nd</sup> ChTx	p-value 1 <sup>st</sup> vs 2 <sup>nd</sup>	Before 3 <sup>rd</sup> ChTx	p-value 1 <sup>st</sup> vs 3 <sup>rd</sup>
n	41	40		35	
EV (x 10 <sup>3</sup> mL <sup>-1</sup> )	429 (288; 664)	376 (225; 584)	0.13	255 (181; 474)	0.007
PLT+EV (x 10 <sup>3</sup> mL <sup>-1</sup> )	216 (129; 287)	171 (104;248)	0.056	119 (74; 210)	0.001
% of EV	50	45		47	
TF+EV (x 10 <sup>3</sup> mL <sup>-1</sup> )	19 (10; 38)	20 (9; 32)	0.58	15 (9; 29)	0.101
% of EV	6	7		6	
D-Dimer (µg mL <sup>-1</sup> )	0.99 (0.48; 2.52)	0.69 (0.50; 3.06)	0.95	0.99 (0.52; 2.17)	0.95
CEA (µg L <sup>-1</sup> )	9.4 (1.9; 42.8)	9.7 (2.6; 70.6)	0.086	9.4 (3.0; 54.9)	0.39

**Methods:** Advanced CRC patients receiving 5-fluorouracil based ChTx were eligible. The number of EV was assessed by flow cytometry in fresh platelet poor plasma obtained from venous blood collected immediately before ChTx. EV were defined by size (forward scatter, < 1 µm) and annexin V binding and labeled using antibodies (anti-CD41a: platelet positive EV [PLT+EV]; anti-CD142: TF positive EV [TF+EV]). D-Dimer was assessed by ELISA. The paired *t*-test was used to compare baseline (BL) levels with levels obtained before ChTx. Data are given in absolute numbers (median [quartiles]) if not otherwise stated.

**Results:** 41 patients (mean age 64 years, 68% men) were included and 35 patients completed 3 cycles of ChTx. Table 1 shows the number of EV, the levels of D-dimer and CEA at BL and before 2<sup>nd</sup> and 3<sup>rd</sup> ChTx, respectively. EV significantly decreased from 429 (288; 664)x10<sup>3</sup> mL<sup>-1</sup> at BL to 255 (181; 474)x10<sup>3</sup> mL<sup>-1</sup> before the 3<sup>rd</sup> cycle. PLT+EV significantly decreased from 216 (129; 287)x10<sup>3</sup> mL<sup>-1</sup> at BL to 119 (74; 210)x10<sup>3</sup> mL<sup>-1</sup> before the 3<sup>rd</sup> cycle. The proportion of PLT+EV ranged from 45%-50% throughout ChTx. Number and proportion of TF+EV were small at all time points. D-dimer levels were 0.99 (0.48; 2.52) µg mL<sup>-1</sup> at BL and did not decrease over the course of ChTx. D-dimer levels did not correlate with the number of EV.

**Conclusions:** In patients with advanced CRC, ChTx attenuates coagulation activation as indicated by a decline of the number of EV.

## PB 676 | The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular Vesicles in Paroxysmal Nocturnal Hemoglobinuria Patients

A. Wannez<sup>1,2</sup>, B. Devalet<sup>2</sup>, C. Bouvy<sup>1</sup>, B. Bihin<sup>2</sup>, J. Douxfils<sup>1</sup>, J.-M. Dogné<sup>1</sup>, F. Mullier<sup>2</sup>

<sup>1</sup>University of Namur, Pharmacy Department, Namur, Belgium, <sup>2</sup>Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

**Background:** Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by a complement-mediated hemolysis. Complement attack induces extracellular vesicles (EV) production. These EV can be implied in thrombus formation, the leading cause of death in PNH patients. Eculizumab, an anti-C5 monoclonal antibody, decreases the thrombosis frequency in PNH.

**Aims:** We wanted to assess the impact of eculizumab on the EV quantification and on their procoagulant activity. The purpose is to check, if the antithrombotic activity of the eculizumab could be, in part, explained by its interaction with the EV.

**Methods:** We recruited 6 PNH patients. Informed consents were obtained for each patient. The study was led according to the declaration of Helsinki and approved by the local Ethic Committee. We collected platelet free plasma (PFP) for each patient before the start of eculizumab, after 4 weeks and after 11 weeks of treatment. We assessed the amount of platelets EV (flow cytometry), the procoagulant activity on PFP (Thrombin generation-TGA), provided by phospholipids (STA®-Procoag-PPL) and by isolated EV (TGA). We used mixed-effects linear regression (R 3.1.2 with nlme package) with logarithmic transformation for flow cytometry results.

**Results:** We compared the results obtained after 4 weeks or after 11 weeks of treatment compared to the value before the start of the treatment. The results on the patient's PFP show a decrease in the amount of platelet EV with the treatment. About the procoagulant activity of the EV, we observed a decrease in the procoagulant profile (PL and EV-induced) with the eculizumab.

**Conclusions:** Eculizumab can play its anti-thrombotic role by an action on the EV. With a bigger cohort, we could estimate a threshold value of the procoagulant activity induced by the EV. The purpose will be to measure the EV activity by STA®-Procoag PPL or TGA on isolated EV in order to assess the thrombotic risk of PNH patients treated with eculizumab.

## PB 677 | Magnetic Capture of Extracellular Vesicles: A Quantitative Flow Cytometry Study

A. Brisson<sup>1</sup>, R. Linares<sup>1</sup>, Y. Boucaud<sup>1</sup>, C. Gounou<sup>1</sup>, S. Tan<sup>1</sup>, L. Adumeau<sup>2</sup>, S. Mornet<sup>2</sup>

<sup>1</sup>University of Bordeaux, UMR-CBMN, Pessac, France, <sup>2</sup>UPR-ICMCB, CNRS, Pessac, France

**Background:** Cells release small membrane vesicles, called microparticles, exosomes or extracellular vesicles (EV), which attract interest for their diverse properties and potential applications. However, EV found in body fluids are heterogeneous, and there is yet no reliable method allowing the isolation of selected EV populations.